The 75 references in paper V. Zimina N., A. Astaf'ev V., В. Зимина Н., А. Астафьев В. (2016) “Внебольничные пневмонии у взрослых больных ВИЧ-инфекцией: особенности течения и лечения, профилактика // Community-acquired pneumonia in adult HIV-infected patients: course, treatment, and prevention” / spz:neicon:pulmonology:y:2016:i:4:p:488-497

1
Федеральный научно-методический центр по профилактике и борьбе со СПИДом ФБУН ЦНИИЭ. Справка «ВИЧ-инфекция в Российской Федерации на 31 декабря 2014 г.». URL: http://www.hivrussia.ru/files/bul_40.pdf (дата обращения: 06.08.2016).
(check this in PDF content)
2
Литвинова Н.Г., Кравченко А.В., Шахгильдян В.И. и др. Поражение нижних дыхательных путей у больных ВИЧ-инфекцией. Эпидемиология и инфекционные болезни.2004; 4: 24–27.
(check this in PDF content)
3
Hirschtick R.E., Glassroth J., Jordan M.C. et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group.N. Engl. J. Med.1995; 28; 333 (13): 845–851.
(check this in PDF content)
4
Twigg H.L., Soliman D.M., Day R.B. et al. Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virusinfection. Am. J. Respir. Crit. Care Med. 1999; 159 (5, Pt 1): 1439–1444.
(check this in PDF content)
5
Jones J.L., Hanson D.L., Dworkin M.S. et al. Surveillance for AIDS-defining opportunistic illnesses, 1992–1997. Morb. Mortal. Wkly. Rep. CDC Surveill. Summ. 1999; 16; 48 (2): 1–22.
(check this in PDF content)
6
Serraino D., Puro V., Boumis E. et al. Epidemiological aspects of major opportunistic infections of the respiratory tract in persons with AIDS: Europe, 1993–2000. AIDS. 2003 26; 17 (14): 2109–2116.
(check this in PDF content)
7
Sullivan J.H., Moore R.D., Keruly J.C. et al. Effect of antiretroviral therapy on the incidence of bacterial pneumonial in patients with advanced HIV infection. Am. J. Respir. Crit. Care Med.2000; 162 (1): 64–67.
(check this in PDF content)
8
Crothers K., Huang L., Goulet J.L. et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am. J. Respir. Crit. Care Med. 2011; 183 (3): 388–395. DOI: 10.1164/rccm.2010060836OC.
(check this in PDF content)
9
Bordon J., Kapoor R., Martinez C. et al. CD4+-cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients.Int. J. Infect. Dis.2011; 15 (12): e822–e827. DOI:
(check this in PDF content)
10
1016/j.ijid.2011.05.021. 10. Chew K.W., Yen I.H., Li J.Z. et al. Predictors of pneumonia severity in HIV-infected adults admitted to an Urban public hospital. AIDS Patient Care STDS. 2011; 13 25 (5): 273–277. DOI: 10.1089/apc.2010.0365.
(check this in PDF content)
11
Segal L.N., MethéB.A., Nolan A. et al. HIV-1 and bacterial pneumonia in the era of antiretroviral therapy.Proc. Am. Thorac. Soc.2011; 8 (3): 282–287. DOI: 10.1513/pats. 201006-044WR.
(check this in PDF content)
12
WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIVRelated Disease in Adults and Children. Geneva: World Health Organisation; 2007. URL: http://www.who.int/hiv/ pub/ guidelines/HIVstaging.pdf (дата обращения: 06.08.2016).
(check this in PDF content)
13
CDC. Revised Surveillance Case Definition for HIV Infection. United States, 2014. Morb. Mortal. Wkly. Rep. Recomm. Rep. 2014; 63 (RR-03): 1–10.
(check this in PDF content)
14
Приказ Минздравсоцразвития РФ от 17.03.06 No 166 «Об утверждении инструкции по заполнению годовой формы федерального государственного и статистического наблюдения No 61 «Сведения о контингентах больных ВИЧ-инфекцией». М.; 2006. URL: http://www. webapteka.ru/phdocs/doc11200.html (дата обращения: 06.08.2016).
(check this in PDF content)
15
Сведения о результатах тестирования представителей различных контингентов на антитела к ВИЧ в субъектах Российской Федерации на 2013–2014 гг. ВИЧ-инфекция. Информационный бюллетень No 40. М.; 2015. URL: http://hivrussia.ru/files/bul_40.pdf(дата обращения: 06.08.2016).
(check this in PDF content)
16
Wallace J.M., Rao A.V., Glassroth J. et al. Respiratory illness in persons with human immunodeficiency virus infection. The Pulmonary Complications of HIV Infection Study Group. Am. Rev. Respir. Dis. 1993; 148 (6, Pt 1): 1523–1529.
(check this in PDF content)
17
Gordin F.M., Roediger M.P., Girard P.M. et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am. J. Respir. Crit. Care Med.2008; 178 (6): 630–636. DOI: 10.1164/rccm.200804617OC.
(check this in PDF content)
18
Grau I., Pallares R., Tubau F. et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human Зимина В.Н., Астафьев А.В.Внебольничные пневмонии у взрослых больных ВИЧ-инфекцией immunodeficiency virus in the era of highly active antiretroviral therapy. Arch. Intern. Med.2005; 165 (13): 1533–1540.
(check this in PDF content)
19
Jones J.L., Hanson D.L., Dworkin M.S. et al. Surveillance for AIDS-defining opportunistic illnesses, 1992–1997. Morb. Mortal. Wkly. Rep. CDC Surveill. Summ.1999; 48 (2): 1–22.
(check this in PDF content)
20
Sullivan J.H., Moore R.D., Keruly J.C. et al. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am. J. Respir. Crit. Care Med.2000; 162 (1): 64–67.
(check this in PDF content)
21
Serraino D., Puro V., Boumis E. et al. Epidemiological aspects of major opportunistic infections of the respiratory tract in persons with AIDS: Europe, 1993–2000. AIDS. 2003; 17 (14): 2109–2116.
(check this in PDF content)
22
Bénard A., MerciéP., Alioum A. et al. Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000–2007. PLoS One.2010; 5 (1): e8896. DOI: 10.1371/ journal.pone.0008896.
(check this in PDF content)
23
Madeddu G., Fiori L.M., Mura S.M. Bacterial communityacquired pneumonia in HIV-infected patients. Curr. Opin. Pulm. Med.2010; 16 (3): 201–207. DOI: 10.1097/MCP. 0b013e3283375825.
(check this in PDF content)
24
Manno D., Puoti M., Signorini L. et al. Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis. Infection. 2009; 37 (4): 334–339. DOI: 10.1007/s15010009-8140-5.
(check this in PDF content)
25
Burack J.H., Hahn J.A., Saint-Maurice D. et al. Microbiology of community-acquired bacterial pneumonia in persons with and at risk for human immunodeficiency virus type 1 infection. Implications for rational empiric antibiotic therapy. Arch. Intern. Med. 1994; 154 (22): 2589–2596.
(check this in PDF content)
26
Miller R.F., Foley N.M., Kessel D. et al. Community acquired lobar pneumonia in patients with HIV infection and AIDS. Thorax. 1994; 49 (4): 367–368.
(check this in PDF content)
27
Mundy L.M., Auwaerter P.G., Oldach D. et al. Community-acquired pneumonia: impact of immune status.Am. J. Respir. Crit. Care Med.1995; 152 (4, Pt 1): 1309–1315.
(check this in PDF content)
28
Afessa B., Green B. Bacterial pneumonia in hospitalized patients with HIV infection: the Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study. Chest. 2000; 117 (4): 1017–1022.
(check this in PDF content)
29
Park D.R., Sherbin V.L., Goodman M.S. et al. The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. J. Infect. Dis. 2001; 184 (3): 268–277.
(check this in PDF content)
30
Rimland D., Navin T.R., Lennox J.L. et al. Prospective study of etiologic agents of community-acquired pneumonia in patients with HIV infection. AIDS. 2002; 16 (1): 85–95.
(check this in PDF content)
31
Tarp B., Jensen J.S., Ostergaard L. et al. Search for agents causing atypical pneumonia in HIV-positive patients by inhibitor-controlled PCR assays.Eur. Respir. J.1999; 13 (1): 175–179.
(check this in PDF content)
32
Diep B.A., Chambers H.F, Graber C.J. et al. Emergence of multidrug-resistant, community-associated, methicillinresistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann. Intern. Med. 2008; 148 (4): 249–257.
(check this in PDF content)
33
Osmond D.H., Chin D.P., Glassroth J. et al. Impact of bacterial pneumonia and Pneumocystis carinii pneumonia on human immunodeficiency virus disease progression. Pulmonary Complications of HIV Study Group. Clin. Infect. Dis.1999; 29 (3): 536–543.
(check this in PDF content)
34
Kohli R., Lo Y., Homel P. et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin. Infect. Dis. 2006; 43 (1): 90–98.
(check this in PDF content)
35
Dworkin M.S., Ward J.W., Hanson D.L. et al. Pneumococcal disease among human immunodeficiency virusinfected persons: incidence, risk factors, and impact of vaccination. Clin. Infect. Dis.2001; 32: 794–800.
(check this in PDF content)
36
Nuorti J.P., Butler J.C., Gelling L. et al. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California.Ann. Intern. Med.2000; 132: 182–190.
(check this in PDF content)
37
Jones N., Huebner R., Khoosal M. et al. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS. 1998; 12 (16): 2177–2184.
(check this in PDF content)
38
Hibbs J.R., Douglas J.M. Jr, Judson F.N. et al. Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984–1994. Clin. Infect. Dis. 1997; 25 (2): 195–199.
(check this in PDF content)
39
Redd S.C., Rutherford G.W., Sande M.A. et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents.J. Infect. Dis. 1990; 162 (5): 1012–1017.
(check this in PDF content)
40
Barry P.M., Zetola N., Keruly J.C. et al. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990–2003. AIDS. 2006; 20 (3): 437–444 DOI: 10.1097/01.aids.0000206507.54901.84.
(check this in PDF content)
41
Heffernan R.T., Barrett N.L., Gallagher K.M. et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995–2000. J. Infect. Dis. 2005; 191 (12): 2038–2204.
(check this in PDF content)
42
Curran A., FalcóV., Crespo M. et al. Bacterial pneumonia in HIV-infected patients: use of the pneumonia severity index and impact of currentmanagement on incidence, aetiology and outcome. HIV Med.2008; 9 (8): 609–615. DOI: 10.1111/j.1468-1293.2008.00603.x.
(check this in PDF content)
43
Cordero E., Pachon J., Rivero A. et al. Communityacquired bacterial pneumonia in human immunodeficiency virus infected patients: validation of severity criteria. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Am. J. Respir. Crit. Care Med. 2000; 162 (6): 2063–2068.
(check this in PDF content)
44
Пархоменко Ю.Г., Зюзя Ю.Р., Флигиль Д.М. Дифференциальная диагностика деструктивных поражений легких при ВИЧ-ассоциированных инфекциях. Архив патологии.2011; 1: 9–12.
(check this in PDF content)
45
Horo K., KonéA.,Koffi M.O. et al. Comparative diagnosis of bacterial pneumonia and pulmonary tuberculosis in HIV positive patients. Rev. Mal. Respir.2016; 33 (1): 47–55. DOI: 10.1016/j.rmr.2015.01.004.
(check this in PDF content)
46
Cilloniz C., Torres A., Polverino E. et al.Communityacquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome.Eur. Respir. J. 2014; 43 (6): 1698–1708. DOI: 10.1183/09031936.00155813.
(check this in PDF content)
47
Selwyn P.A., Pumerantz A.S., Durante A. et al. Clinical predictors of Pneumocystis carinii pneumonia, bacterialpneumonia and tuberculosis in HIV-infected patients. AIDS. 1998; 12 (8): 885–893.
(check this in PDF content)
48
Сайт Федеральной службы государственной статистики. URL:http://www.gks.ru/wps/wcm/connect/rosstat_ main/rosstat/ru/statistics/population/healthcare/#(дата обращения 08.08.16).
(check this in PDF content)
49
Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Chapter «Bacterial Respi ratory Disease». 2014; 97–109. Available at https://aidsinfo. nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/327/bacterial-respiratory (дата обращения 08.08.2016).
(check this in PDF content)
50
Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Российское респираторное общество (РРО) Межрегиональная ассоциация по клинической микробиологии и антимикробной химиотерапии (МАКМАХ). Клинические рекомендации по диагностике, лечению и профилактике тяжелой внебольничной пневмонии у взрослых. Пульмонология. 2014; 4: 13–48.
(check this in PDF content)
51
Гаращенко Т.И., Геппе Н.А., Гомберг М.А. и др. Роль и место современных макролидов в лечении бактериальных инфекций. Клиническая микробиология и антимикробная химиотерапия. 2014; 16 (1); 78–84.
(check this in PDF content)
52
Porwal C., Kaushik A., Makkar N. et al. Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region.PLoS One. 2013; 8 (2): e55299. DOI: 10.1371/journal.pone.0055299.
(check this in PDF content)
53
Chen T.C., Lu P.L., Lin C.Y. et al. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int. J. Infect. Dis.2011; 15 (3): e211–e216.
(check this in PDF content)
54
Devasia R.A., Blackman A., Gebretsadik T. et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am. J. Respir. Crit. Care Med. 2009; 180 (4): 365–370. DOI: 10.1164/rccm.200901-0146OC.
(check this in PDF content)
55
These guidelines were developed in compliance with the process for evidence gathering, assessment and formulation of recommendations, as outlined in the WHO Handbook for Guideline Development. 2014. WHO Treatment guidelines for drug-resistant tuberculosis – 2016 update. March; Available athttp:// www.who.int/kms/handbook_2nd_ed.pdf
(check this in PDF content)
56
García Vázquez E., Mensa J., Martínez J.A. et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone.Eur. J. Clin. Microbiol. Infect. Dis. 2005; 24 (3): 190–195.
(check this in PDF content)
57
Nie W., Li B., Xiu Q. β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of communityacquired pneumonia in adults: a systematic review and meta-analysis. J. Antimicrob. Chemother. 2014; 69 (6): 1441–1446. DOI: 10.1093/jac/dku033.
(check this in PDF content)
58
Martin-Loeches I., Lisboa T., Rodriguez A. et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia.Intens. Care Med.2010; 36 (4): 612–620. DOI: 10.1007/s00134-009-1730-y.
(check this in PDF content)
59
Restrepo M.I., Mortensen E.M., Waterer G.W. et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur. Respir. J.2009; 33 (1): 153–159. DOI: 10.1183/09031936.00054108.
(check this in PDF content)
60
Lodise T.P., Kwa A., Cosler L. et al. Comparison of betalactam and macrolide combination therapy versus fluoroquinolone monotherapy inhospitalized Veterans Affairs patients withcommunity-acquiredpneumonia. Antimicrob. Agents Chemother. 2007; 51 (11): 3977–3982.
(check this in PDF content)
61
Clinical Guidelines Portal. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Bacterial Respiratory Disease. Available at: https://aidsinfo.nih.gov/guidelines/html/4/ adult-and-adolescent-oi-prevention-and-treatment-guidelines/327/bacterial-respiratory
(check this in PDF content)
62
Чучалин А.Г., Биличенко Т.Н., Осипова Г.Л. и др. Вакцинопрофилактика болезней органов дыхания в рамках первичной медико-санитарной помощи населению. Клинические рекомендации. Пульмонология: прил. 2015; 25 (2): 1–20. http://www.pulmonology.ru/download/ Prilogenie_2015_final.pdf (дата обращения 08.08.2016).
(check this in PDF content)
63
Фельдблюм И.В., Николенко В.В., Воробьева Н.Н. и др. Реактогенность, безопасность, иммуногенность и профилактическая эффективность полисахаридной пневмококковой вакцины при иммунизации ВИЧ-инфицированных пациентов. Журнал микробиологии, эпидемиологии и иммунобиологии.2013; 3: 52–60.
(check this in PDF content)
64
Gebo K.A., Moore R.D., Keruly J.C. et al. Risk factors for pneumococcal disease in human immunodeficiency virusinfected patients. J. Infect. Dis.1996; 173 (4): 857–862.
(check this in PDF content)
65
Guerrero M., Kruger S., Saitoh A. et al. Pneumonia in HIV-infected patients: a case-control survey of factors involved in risk and prevention. AIDS. 1999; 13 (14): 1971–1975.
(check this in PDF content)
66
Breiman R.F., Keller D.W., Phelan M.A. et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch. Int. Med.2000; 160 (17): 2633–2638.
(check this in PDF content)
67
Recommended Adult Immunization Schedule. United States, October 2007–September 2008. Morb. Mortal. Wkly. Rep. 2007; 56: Q1–Q4.
(check this in PDF content)
68
Hung C.C., Chen M.Y., Hsieh S.M. et al. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine. 2004; 22 (15–16): 2006–2012.
(check this in PDF content)
69
Peñaranda M., Falco V., Payeras A. et al. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study. Clin. Infect. Dis.2007; 45 (7): e82–e87.
(check this in PDF content)
70
Fiore A.E., Uyeki T.M., Broder K. et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. Morb. Mortal. Wkly. Rep. Recomm. Rep.2010; 59 (RR-8): 1–62.
(check this in PDF content)
71
Sibanda E.L., Weller Ian V.D., Hakim J.G. et al. Does trimethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes? Results of a systematic review. Clin. Infect. Dis.2011; 52 (9): 1184–1194. DOI: 10.1093/cid/cir067.
(check this in PDF content)
72
Hirschtick R.E., Glassroth J., Jordan M.C. et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N. Engl. J. Med. 1995; 333 (13): 845–851.
(check this in PDF content)
73
Eigenmann C., Flepp M., Bernasconi E. et al. Low incidence of community-acquired pneumonia among Human Immunodeficiency Virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis. Clin. Infect. Dis. 2003; 36: 917–921.
(check this in PDF content)
74
Hamel M.J., Greene C., Chiller T. et al. Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select forresistant pathogens in Зимина В.Н., Астафьев А.В.Внебольничные пневмонии у взрослых больных ВИЧ-инфекцией Kenyan adults? Am. J. Trop. Med. Hyg.2008; 79 (3): 320–330.
(check this in PDF content)
75
EACS. GUIDELINES. Version 8.0. October 2015. English. Available at: www.eacsociety.org/files/guidelines_8_0-english_ web.pdf/(дата обращения 08.08.16). Поступила 02.09.16 УДК [616.98:578.828.6]906:616.249002
(check this in PDF content)